Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 12, 2004

Primary Completion Date

January 5, 2017

Study Completion Date

January 5, 2017

Conditions
Leukemia
Interventions
DRUG

GM-CSF (Sargramostim)

250 mcg injection under the skin, three times a week for eight weeks.

DRUG

Rituximab

375 mg/m\^2 administered intravenously once weekly for four weeks

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER